Answers are grounded in this paper and cite their sources.
Adjuvant therapy with induction BCG followed by maintenance BCG is the appropriate standard of care for patients with resected NMIBC at high risk of recurrence. Further trials are warranted to test the effects of adding chemotherapy to BCG in patients with Ta or T1 disease, but not in those with Tis alone.
No takes yet. Share an insight, caveat, or question.
Houghton et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: